{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:07Z","timestamp":1791834967816,"version":"4.3.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T00:00:00Z","timestamp":1607731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Impulse control disorders (ICDs) have been described as a side effect of dopamine agonists (DAs) in neurological as well as endocrine conditions. Few studies have evaluated the neuropsychological effect of DAs in hyperprolactinemic patients, and these have reported a relationship between DAs and ICDs. Our objective was to screen for ICD symptoms in individuals with DA-treated endocrine conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A cross-sectional analysis was conducted on 132 patients with pituitary disorders treated with DAs (DA exposed), as well as 58 patients with pituitary disorders and no history of DA exposure (non-DA exposed). Participants responded to the full version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson\u2019s disease (QUIP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with the non-DA-exposed group, a higher prevalence of DA-exposed patients tested positive for symptoms of any ICD or related behavior (52% vs. 31%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), any ICD (46% vs. 24%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), any related behavior (31% vs. 17%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), compulsive sexual behavior (27% vs. 14%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.04), and punding (20% vs. 7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.02) by QUIP. On univariate analysis, DA treatment was associated with a two- to threefold increased risk of any ICD or related behavior [odds ratio (OR) 2.43] and any ICD (OR 2.70). In a multivariate analysis, independent risk factors for any ICD or related behavior were DA use (adjusted OR 2.22) and age (adjusted OR 6.76). Male gender was predictive of the risk of hypersexuality (adjusted OR 3.82).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Despite the QUIP limitations, a clear sign of increased risk of ICDs emerges in individuals with DA-treated pituitary disorders. Our data contribute to the growing evidence of DA-induced ICDs in endocrine conditions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-020-01478-0","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T12:02:37Z","timestamp":1607774557000},"page":"1699-1706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study"],"prefix":"10.1007","volume":"44","author":[{"given":"G.","family":"Beccuti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Natta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Cambria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Prencipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cicolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Montanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Lopiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ghigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zibetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grottoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,12]]},"reference":[{"key":"1478_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2011.00001","volume":"2","author":"L Schreiber","year":"2011","unstructured":"Schreiber L, Odlaug BL, Grant JE (2011) Impulse control disorders: updated review of clinical characteristics and pharmacological management. Front Psychiatry 2:1. https:\/\/doi.org\/10.3389\/fpsyt.2011.00001","journal-title":"Front Psychiatry"},{"key":"1478_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fneur.2019.00351","volume":"10","author":"EM Gatto","year":"2019","unstructured":"Gatto EM, Aldinio V (2019) Impulse control disorders in Parkinson\u2019s disease a brief and comprehensive review. Front Neurol 10:351. https:\/\/doi.org\/10.3389\/fneur.2019.00351","journal-title":"Front Neurol"},{"issue":"4","key":"1478_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/1520-6394(2000)11:4<185::AID-DA8>3.0.CO;2-H","volume":"11","author":"S Seedat","year":"2000","unstructured":"Seedat S, Kesler S, Niehaus DJ, Stein DJ (2000) Pathological gambling behaviour: emergence secondary to treatment of Parkinson\u2019s disease with dopaminergic agents. Depress Anxiety 11(4):185\u2013186. https:\/\/doi.org\/10.1002\/1520-6394(2000)11:4%3c185::AID-DA8%3e3.0.CO;2-H","journal-title":"Depress Anxiety"},{"key":"1478_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","volume":"133","author":"D Weintraub","year":"2017","unstructured":"Weintraub D, Claassen DO (2017) Impulse control and related disorders in Parkinson\u2019s disease. Int Rev Neurobiol 133:679\u2013717. https:\/\/doi.org\/10.1016\/bs.irn.2017.04.006","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"1478_CR5","first-page":"81","volume":"33","author":"JR Cornelius","year":"2010","unstructured":"Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH (2010) Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33(1):81\u201387","journal-title":"Sleep"},{"issue":"1","key":"1478_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","volume":"104","author":"JE Ahlskog","year":"2011","unstructured":"Ahlskog JE (2011) Pathological behaviors provoked by dopamine agonist therapy of Parkinson\u2019s disease. Physiol Behav 104(1):168\u2013172. https:\/\/doi.org\/10.1016\/j.physbeh.2011.04.055","journal-title":"Physiol Behav"},{"issue":"2","key":"1478_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1478_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","volume":"19","author":"M Davie","year":"2007","unstructured":"Davie M (2007) Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci 19(4):473\u2013474. https:\/\/doi.org\/10.1176\/jnp.2007.19.4.473","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"1478_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","volume":"190","author":"H Falhammar","year":"2009","unstructured":"Falhammar H, Yarker JY (2009) Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust 190(2):97","journal-title":"Med J Aust"},{"issue":"8","key":"1478_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1055\/s-0031-1281580","volume":"79","author":"M Gahr","year":"2011","unstructured":"Gahr M, Connemann BJ, Sch\u00f6nfeldt-Lecuona CJ (2011) Pathological gambling induced by dopamine agonists. Fortschr Neurol Psychiatr 79(8):470\u2013474. https:\/\/doi.org\/10.1055\/s-0031-1281580","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"5","key":"1478_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P (2011) Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol 34(5):179\u2013181. https:\/\/doi.org\/10.1097\/WNF.0b013e3182281b2f","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1478_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.psym.2012.10.002","volume":"54","author":"S Almanzar","year":"2013","unstructured":"Almanzar S, Zapata-Vega MI, Raya JA (2013) Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. Psychosomatics 54(4):387\u2013391. https:\/\/doi.org\/10.1016\/j.psym.2012.10.002","journal-title":"Psychosomatics"},{"issue":"5","key":"1478_CR13","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","volume":"36","author":"SK Thondam","year":"2013","unstructured":"Thondam SK, Alusi S, O\u2019Driscoll K, Gilkes CE, Cuthbertson DJ, Daousi C (2013) Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin Neuropharmacol 36(5):170\u2013172. https:\/\/doi.org\/10.1097\/WNF.0b013e31829fc165","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"1478_CR14","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","volume":"55","author":"SM De Sousa","year":"2017","unstructured":"De Sousa SM, Chapman IM, Falhammar H, Torpy DJ (2017) Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine 55(2):618\u2013624. https:\/\/doi.org\/10.1007\/s12020-016-1088-1","journal-title":"Endocrine"},{"issue":"6","key":"1478_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case\u2013control study. Clin Endocrinol (Oxf) 80(6):863\u2013868. https:\/\/doi.org\/10.1111\/cen.12375","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"1478_CR16","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z et al (2019) Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab 104(7):2527\u20132534. https:\/\/doi.org\/10.1210\/jc.2018-02202","journal-title":"J Clin Endocrinol Metab"},{"key":"1478_CR17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz076","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL, Butler J, Sorbello J, Vorster J et al (2020) Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz076","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"1478_CR18","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","volume":"62","author":"E Celik","year":"2018","unstructured":"Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P (2018) Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine 62(3):692\u2013700. https:\/\/doi.org\/10.1007\/s12020-018-1744-8","journal-title":"Endocrine"},{"issue":"10","key":"1478_CR19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED et al (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord 24(10):1461\u20131467. https:\/\/doi.org\/10.1002\/mds.22571","journal-title":"Mov Disord"},{"issue":"2","key":"1478_CR20","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1136\/jnnp-2014-307904","volume":"86","author":"ML Fantini","year":"2015","unstructured":"Fantini ML, Macedo L, Zibetti M, Sarchioto M, Vidal T, Pereira B et al (2015) Increased risk of impulse control symptoms in Parkinson\u2019s disease with REM sleep behaviour disorder. J Neurol Neurosurg Psychiatry 86(2):174\u2013179. https:\/\/doi.org\/10.1136\/jnnp-2014-307904","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"1478_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2013.02.028","volume":"328","author":"PS Koekkoek","year":"2013","unstructured":"Koekkoek PS, Rutten GE, van den Berg E, van Sonsbeek S, Gorter KJ, Kappelle LJ et al (2013) The \u201cTest Your Memory\u201d test performs better than the MMSE in a population without known cognitive dysfunction. J Neurol Sci 328(1\u20132):92\u201397. https:\/\/doi.org\/10.1016\/j.jns.2013.02.028","journal-title":"J Neurol Sci"},{"issue":"3","key":"1478_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s005200050241","volume":"7","author":"M Costantini","year":"1999","unstructured":"Costantini M, Musso M, Viterbori P, Bonci F, Del Mastro L, Garrone O et al (1999) Detecting psychological distress in cancer patients: validity of the Italian version of the Hospital Anxiety and Depression Scale. Support Care Cancer 7(3):121\u2013127. https:\/\/doi.org\/10.1007\/s005200050241","journal-title":"Support Care Cancer"},{"issue":"3","key":"1478_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000335996","volume":"96","author":"AP Athanasoulia","year":"2012","unstructured":"Athanasoulia AP, Ising M, Pfister H, Mantzoros CS, Stalla GK, Sievers C (2012) Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 96(3):204\u2013211. https:\/\/doi.org\/10.1159\/000335996","journal-title":"Neuroendocrinology"},{"issue":"2","key":"1478_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","volume":"17","author":"M Barake","year":"2014","unstructured":"Barake M, Evins AE, Stoeckel L, Pachas GN, Nachtigall LB, Miller KK et al (2014) Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 17(2):150\u2013156. https:\/\/doi.org\/10.1007\/s11102-013-0480-6","journal-title":"Pituitary"},{"issue":"5","key":"1478_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67(5):589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"issue":"1","key":"1478_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","volume":"41","author":"M Grall-Bronnec","year":"2018","unstructured":"Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E et al (2018) Dopamine agonists and impulse control disorders: a complex association. Drug Saf 41(1):19\u201375. https:\/\/doi.org\/10.1007\/s40264-017-0590-6","journal-title":"Drug Saf"},{"issue":"2","key":"1478_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1176\/appi.ajp.158.2.308","volume":"158","author":"V Kaasinen","year":"2001","unstructured":"Kaasinen V, N\u00e5gren K, Hietala J, Farde L, Rinne JO (2001) Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry 158(2):308\u2013311. https:\/\/doi.org\/10.1176\/appi.ajp.158.2.308","journal-title":"Am J Psychiatry"},{"issue":"7","key":"1478_CR28","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1017\/S1461145711001957","volume":"15","author":"AK Brown","year":"2012","unstructured":"Brown AK, Mandelkern MA, Farahi J, Robertson C, Ghahremani DG, Sumerel B et al (2012) Sex differences in striatal dopamine D2\/D3 receptor availability in smokers and non-smokers. Int J Neuropsychopharmacol 15(7):989\u2013994. https:\/\/doi.org\/10.1017\/S1461145711001957","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"1478_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/cne.20229","volume":"476","author":"LM Creutz","year":"2004","unstructured":"Creutz LM, Kritzer MF (2004) Mesostriatal and mesolimbic projections of midbrain neurons immunoreactive for estrogen receptor beta or androgen receptors in rats. J Comp Neurol 476(4):348\u2013362. https:\/\/doi.org\/10.1002\/cne.20229","journal-title":"J Comp Neurol"},{"issue":"5","key":"1478_CR30","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/adb.12381","volume":"21","author":"L Fattore","year":"2016","unstructured":"Fattore L, Melis M (2016) Sex differences in impulsive and compulsive behaviors: a focus on drug addiction. Addict Biol 21(5):1043\u20131051. https:\/\/doi.org\/10.1111\/adb.12381","journal-title":"Addict Biol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01478-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-020-01478-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01478-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T07:10:36Z","timestamp":1626419436000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-020-01478-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,12]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1478"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01478-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,12]]},"assertion":[{"value":"6 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the appropriate institutional ethics committee (\u201cCity of Health and Science of Turin\u201d University Hospital) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}